Edie Weller

16.3k total citations · 3 hit papers
131 papers, 7.5k citations indexed

About

Edie Weller is a scholar working on Hematology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Edie Weller has authored 131 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 44 papers in Pathology and Forensic Medicine and 39 papers in Oncology. Recurrent topics in Edie Weller's work include Lymphoma Diagnosis and Treatment (43 papers), Multiple Myeloma Research and Treatments (30 papers) and Chronic Lymphocytic Leukemia Research (28 papers). Edie Weller is often cited by papers focused on Lymphoma Diagnosis and Treatment (43 papers), Multiple Myeloma Research and Treatments (30 papers) and Chronic Lymphocytic Leukemia Research (28 papers). Edie Weller collaborates with scholars based in United States, Canada and France. Edie Weller's co-authors include Kenneth C. Anderson, Sandra J. Horning, Thomas M. Habermann, Randy D. Gascoyne, Paul G. Richardson, Irene M. Ghobrial, Robert Schlossman, B. A. Peterson, Richard I. Fisher and Peter A. Cassileth and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Edie Weller

126 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

2006 997 citations Thomas M. Habermann, Edie Weller et al. profile →
BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression

2013 645 citations Federico Campigotto, Edie Weller et al. profile →
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

2002 630 citations Robert Schlossman, Edie Weller et al. Blood profile →

Peers

Edie Weller

ONCOL

PFM

HEMAT

GENET

Lorenz Trümper Germany

David J. Inwards United States

Luca Arcaini Italy

Alfred Reiter Germany

Jean‐Yves Cahn France

Andrew Jack United Kingdom

Michael Crump Canada

John Kuruvilla Canada

A. Z. S. Rohatiner United Kingdom

Peter Mauch United States

Lorenz Trümper Germany

Edie Weller

3.3k ×1.0

ONCOL

3.9k ×1.3

PFM

1.0k ×0.4

HEMAT

1.9k ×0.8

2.1k ×1.2

GENET

Citations per year, relative to Edie Weller Edie Weller (= 1×) peers Lorenz Trümper

Countries citing papers authored by Edie Weller

Since Specialization

Citations

This map shows the geographic impact of Edie Weller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edie Weller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edie Weller more than expected).

Fields of papers citing papers by Edie Weller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edie Weller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edie Weller. The network helps show where Edie Weller may publish in the future.

Co-authorship network of co-authors of Edie Weller

This figure shows the co-authorship network connecting the top 25 collaborators of Edie Weller. A scholar is included among the top collaborators of Edie Weller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edie Weller. Edie Weller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Jessica, et al.. (2026). Pediatric out-of-hospital cardiac arrest outcomes by Child Opportunity Index, race and ethnicity. Resuscitation. 220. 110970–110970.

Weller, Edie, Marian H. Harris, Christopher R. Reilly, et al.. (2025). Lymphoid malignancies in patients with Shwachman-Diamond syndrome. Blood. 145(21). 2528–2532.

Chang, Joyce C., Emily A. Smitherman, Gabrielle Morgan, et al.. (2025). Multicenter Study of Associations Between Area‐Level Child Opportunity, Initial Disease Severity, and Outcomes Among Children with Lupus. Arthritis Care & Research. 77(8). 965–974.

He, Jie, Laura Berbert, Edie Weller, et al.. (2024). Racial Disparities and Achievement of the Low Lupus Disease Activity State: A CARRA Registry Study. Arthritis Care & Research. 77(1). 38–49. 3 indexed citations

Weller, Edie, Jason E. Farrar, Christopher Gamper, et al.. (2023). Lymphoid Malignancies in Shwachman-Diamond Syndrome: Incidence, Clinical Features, and Outcomes from the North American SDS Registry. Blood. 142(Supplement 1). 5662–5662.

Rosen, Dennis, Laura Berbert, & Edie Weller. (2020). High prevalence of periodic limb movements of sleep in children with Down syndrome. Journal of Clinical Sleep Medicine. 16(3). 347–352. 6 indexed citations

Knoerl, Robert, Edie Weller, Barbara Halpenny, & Donna L. Berry. (2018). Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy. BMC Cancer. 18(1). 1203–1203. 14 indexed citations

Leleu, Xavier, Wanling Xie, Ranjit Banwait, et al.. (2011). The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia. Clinical Cancer Research. 17(9). 3013–3018. 36 indexed citations

Banwait, Ranjit, Kevin O′Regan, Federico Campigotto, et al.. (2011). The role of ¹⁸F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia. American Journal of Hematology. 86(7). 567–572. 36 indexed citations

10.

Winter, Jane N., Shuli Li, Daina Variakojis, et al.. (2010). Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494. Clinical Cancer Research. 16(8). 2435–2442. 26 indexed citations

11.

Ganjoo, Kristen N., Caroline An, Michael J. Robertson, et al.. (2006). Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leukemia & lymphoma. 47(6). 998–1005. 83 indexed citations

12.

Li, Ruifeng, Edie Weller, Douglas W. Dockery, Lucas Neas, & Donna Spiegelman. (2006). Association of indoor nitrogen dioxide with respiratory symptoms in children: Application of measurement error correction techniques to utilize data from multiple surrogates. Journal of Exposure Science & Environmental Epidemiology. 16(4). 342–350. 12 indexed citations

13.

Portenoy, Russell K., Montserrat Rué, Tito R. Mendoza, et al.. (2005). Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group. Annals of Oncology. 16(6). 972–980. 50 indexed citations

14.

Habermann, Thomas M., Edie Weller, V. A. Morrison, et al.. (2004). Rituximab-CHOP Versus CHOP with or without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update.. Blood. 104(11). 127–127. 42 indexed citations

15.

Wadler, Scott, Donna E. Levy, Carla I. Falkson, et al.. (2004). A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Gynecologic Oncology. 92(3). 957–964. 39 indexed citations

16.

Lin, Thomas S., David Zahrieh, Edie Weller, et al.. (2002). Risk factors for cytomegalovirus reactivation after CD6+ T-cell???depleted allogeneic bone marrow transplantation1. Transplantation. 74(1). 49–54. 25 indexed citations

17.

Alyea, Edwin P., Edie Weller, David C. Fisher, et al.. (2002). Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation. 8(11). 601–607. 19 indexed citations

18.

Rajdev, Lakshmi, Zi‐Fan Yu, Scott Wadler, et al.. (2001). N-Methylformamide in Advanced Squamous Cancer of the Uterine Cervix: An Eastern Cooperative Oncology Group Phase II Trial. Investigational New Drugs. 19(3). 233–237. 5 indexed citations

19.

Saphner, Thomas J., Edie Weller, Douglass C. Tormey, et al.. (2000). 21-Day Oral Etoposide for Metastatic Breast Cancer. American Journal of Clinical Oncology. 23(3). 258–262. 19 indexed citations

20.

Barrett, A. John, Edie Weller, Nora Rozengurt, P Longhurst, & J G Humble. (1976). Amidopyrine agranulocytosis:drug inhibition of granulocyte colonies in the presence of patient's serum.. BMJ. 2(6040). 850.2–851. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact